Vyuhpharma

AbbVie *(EC, Approval)*

European Commission Approves AbbVie's RINVOQ® (upadacitinib) for Treatment of Giant Cell Arteritis in Adults

---

Johnson & Johnson *(Clinica data, Phase 3)*

Johnson & Johnson highlights 18-Month data from its Phase 3 Vivacity-MG3, demonstrating nipocalimab's sustained reduction in IgG antibodies and continued improvement in gMG symptoms

---

Johnson & Johnson + Halozyme Therapeutics *(EC, Approval)*

European Commission grants approval for Johnson & Johnson's SC RYBREVANT® with ENHANZE® in patients with advanced EGFR-mutated non-small cell lung cancer

---

Remegen *(Clinica data, Phase 3)*

Remegen reports positive topline Phase 3 data for telitacicept in gMG: 98.1% achieve clinically meaningful MG-ADL improvement; 87% show QMG score reduction at week 24

Avidity Biosciences *(Ophan Drug Designation)*

Avidity Biosciences secures Orphan Drug Designation in Japan for delpacibart etedesiran, supporting ongoing development in myotonic dystrophy type 1

Vyuhpharma

Halozyme Therapeutics *(EC, Approval)*

Halozyme and Janssen receive European Commission approval for SC DARZALEX® with ENHANZE® in combination with VRd for newly diagnosed multiple myeloma

---

Belief BioMed + Takeda *(NMPA, Approval)*

Belief BioMed and Takeda China announce NMPA approval of BBM-H901 (dalnacogene ponparvovec injection), China's first hemophilia B gene therapy

---

Accord Healthcare *(CHMP Opinion)*

CHMP issues positive opinion for Accord Healthcare's denosumab, OSVYRTI, and JUBEREQ

Biocon *(FDA, Approval)*

FDA approves Biocon Biologics' JOBEVNE™ (biosimilar bevacizumab), strengthening its oncology portfolio

---

Belief BioMed + Takeda *(NMPA, Approval)*

Belief BioMed and Takeda China announce NMPA approval of BBM-H901 (dalnacogene ponparvovec injection), China's first hemophilia B gene therapy